Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofitamab Combined With GemOx in Refractory DLBCL
NCT07480850Phase 2
Key facts
- Status
- Active, not recruiting
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Countries
- 1
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Drugs
- glofitamab
- Conditions
- diffuse large B-cell lymphoma (DLBCL)
01
Overview
Phase 2, open-label, single-arm trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Complete Response Rate at 8 weeks. Started Jan 2026; status: active, not recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Refractory diffuse large B-cell lymphoma
Glofitamab + Gemcitabine + Oxaliplatin + Obinutuzumab
03
Who it enrols
Adult patients with refractory DLBCL who are PET-positive after 3 cycles of first-line treatment, with adequate organ function and no CNS involvement.
04
Endpoints
Primary
Complete Response Rate
Secondary
Objective Response Rate
Overall Survival
Progression-Free Survival
Duration of Response
Beyond the preview
Go deeper on NCT07480850.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07480850.